ID   SK-MEL-249
AC   CVCL_6961
SY   JU-MEL
DR   Wikidata; Q54953978
RX   PubMed=7814883;
RX   PubMed=9598804;
CC   From: Memorial Sloan Kettering Cancer Center; New York; USA.
CC   Sequence variation: Gene deletion; HGNC; HGNC:1787; CDKN2A; Zygosity=Homozygous (PubMed=9598804).
CC   Sequence variation: Gene deletion; HGNC; HGNC:1788; CDKN2B; Zygosity=Homozygous (PubMed=9598804).
DI   NCIt; C3224; Melanoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
CA   Cancer cell line
DT   Created: 04-04-12; Last updated: 19-12-24; Version: 13
//
RX   PubMed=7814883; DOI=10.4049/jimmunol.154.2.772;
RA   Takahashi T., Chapman P.B., Yang S.Y., Hara I., Vijayasaradhi S.,
RA   Houghton A.N.;
RT   "Reactivity of autologous CD4+ T lymphocytes against human melanoma.
RT   Evidence for a shared melanoma antigen presented by HLA-DR15.";
RL   J. Immunol. 154:772-779(1995).
//
RX   PubMed=9598804; DOI=10.1002/(SICI)1098-2264(199806)22:2<157::AID-GCC11>3.0.CO;2-N;
RA   Walker G.J., Flores J.F., Glendening J.M., Lin A.H.-T., Markl I.D.C.,
RA   Fountain J.W.;
RT   "Virtually 100% of melanoma cell lines harbor alterations at the DNA
RT   level within CDKN2A, CDKN2B, or one of their downstream targets.";
RL   Genes Chromosomes Cancer 22:157-163(1998).
//